InflaRx NV
IFRX1.270USD
-0.110-7.97%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
86.04MMarket Cap
LossP/E TTM
More Details of InflaRx NV Company
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV Info
Ticker SymbolIFRX
Company nameInflaRx NV
IPO dateNov 08, 2017
CEOProf. Niels C. Riedemann, M.D., Ph.D
Number of employees74
Security typeOrdinary Share
Fiscal year-endNov 08
AddressWinzerlaer Str. 2
CityJENA
Stock exchangeNASDAQ Global Select Consolidated
CountryGermany
Postal code07745
Phone493641508180
Websitehttps://www.inflarx.de/
Ticker SymbolIFRX
IPO dateNov 08, 2017
CEOProf. Niels C. Riedemann, M.D., Ph.D
Company Executives of InflaRx NV
Name
Name/Position
Position
Shareholding
Change
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Revenue Breakdown
Currency: USDUpdated: Wed, Mar 5
Currency: USDUpdated: Wed, Mar 5
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
Germany
0.00
0.00%
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Oct 28
Updated: Tue, Oct 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
9.57%
683 Capital Management LLC
3.65%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
Eversept Partners, LP
2.42%
Other
78.84%
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
9.57%
683 Capital Management LLC
3.65%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
Eversept Partners, LP
2.42%
Other
78.84%
Shareholder Types
Shareholders
Proportion
Hedge Fund
18.89%
Individual Investor
6.38%
Venture Capital
2.91%
Research Firm
1.48%
Investment Advisor
0.73%
Investment Advisor/Hedge Fund
0.52%
Bank and Trust
0.02%
Other
69.08%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
77
16.71M
24.67%
-5.41M
2025Q2
85
22.06M
37.46%
-406.65K
2025Q1
87
22.59M
33.65%
+61.67K
2024Q4
86
18.09M
26.94%
-3.90M
2024Q3
81
17.30M
28.32%
-4.75M
2024Q2
83
17.63M
29.02%
-4.11M
2024Q1
87
18.26M
30.09%
-4.67M
2023Q4
91
21.52M
35.62%
-5.82M
2023Q3
89
23.41M
42.05%
-4.60M
2023Q2
95
25.76M
47.58%
+2.86M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Suvretta Capital Management, LLC
6.48M
9.57%
--
--
Jun 30, 2025
683 Capital Management LLC
2.48M
3.65%
-150.00K
-5.71%
Jun 30, 2025
RA Capital Management, LP
1.97M
2.91%
+1.97M
--
Jun 30, 2025
Guo (Renfeng M.D.)
1.76M
2.6%
--
--
Dec 31, 2024
Eversept Partners, LP
1.64M
2.42%
-35.55K
-2.12%
Jun 30, 2025
Riedemann (Niels C. M.D.)
1.07M
1.58%
--
--
Dec 31, 2024
Mark (Christian Kubler)
960.01K
1.42%
--
--
Dec 31, 2024
Woodline Partners LP
751.27K
1.11%
+283.00
+0.04%
Jun 30, 2025
Ikarian Capital LLC
705.01K
1.04%
+705.01K
--
Jun 30, 2025
Morgan Stanley & Co. LLC
693.35K
1.02%
-567.80K
-45.02%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
